Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vibegron - Kyorin/Urovant Sciences

Drug Profile

Vibegron - Kyorin/Urovant Sciences

Alternative Names: Beova; KRP-114V; MK-4618; RVT 901; URO 901

Latest Information Update: 06 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Kyorin Pharmaceutical; Merck & Co; Urovant Sciences
  • Class Analgesics; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase II Pain
  • Discontinued Endocrine disorders

Most Recent Events

  • 30 Dec 2019 Sumitomo Dainippon Pharma acquired all rights of five companies namely Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences from Riovant and transferred it to Sumitovant Biopharma (a subsidiary of Sumitomo Dainippon Pharma)
  • 30 Dec 2019 Preregistration for Overactive bladder in USA (PO)
  • 07 Nov 2019 Jeil Pharmaceutical in-licenses vibegron from Kyorin Pharmaceutical in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top